Outcomes of Allogeneic Transplantation for Adult T-Cell Leukemia/Lymphoma in Adolescents and Young Adult (AYA) and Young Patients
Authors: Itonaga Hidehiro , Fukushima Takuya , Kato Koji , Nakano Nobuaki , Kato Takeharu , Tanaka Takashi , Eto Tetsuya , Mori Yasuo , Kawakita Toshiro , Uchida Naoyuki , Sawayama Yasushi , Fukuda Takahiro , Kanda Yoshinobu , Atsuta Yoshiko , Yoshimitsu Makoto , Fuji Shigeo 
Published: December 2023

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a durable remission for patients with adult T-cell leukemia/lymphoma (ATL). Reduced-intensity regimens (RIC) have been increasingly used in ATL patients due to their old age and higher non-relapse mortality. However, the role of RIC regimen has not been fully evaluated among ATL patients aged &lt;50 years. We here conducted a nationwide study to evaluate the prognostic impact of conditioning intensity on the post-transplant outcomes in ATL patients aged &lt;50 years.

Methods

The clinical data of patients aged &lt;50 years who underwent their first allo-HSCT between January 2001 and December 2020 were collected from the Transplant Registry Unified Management Program of the Japan Society for Hematopoietic Cell Transplantation. Cox proportional hazards regression models were used to evaluate variables potentially affecting overall survival (OS), graft-versus-host disease (GVHD)- and relapse-free survival (GRFS), and chronic GVHD-free survival (CRFS). Fine and Gray proportional hazards models were used to evaluate variables potentially affecting cumulative incidences of relapse (CIR) and non-relapse mortality (NRM). CIR and NRM were estimated using cumulative incidence curves to accommodate competing events. A two-sided P-value ≤0.05 was considered to be significant. To examine the effect modification, a threshold for P interaction &lt;0.10 was used to indicate significant differences across prespecified subgroups.

Results

This study included 73 and 330 patients who were &lt;40 years old (adolescents and young adults [AYA] patients) and 40-49 years old (young patients), respectively. In AYA patients, the median age at HSCT was 36 years (range, 20-39). RIC regimen was used in 16 out of 57 AYA patients (21.9%), and in 74 out of 330 young patients (22.4%) (P=1.000). There was no significant difference of the patient characteristics regarding comorbidity, performance status at HSCT, disease status, clinical subtype, and donor type.

The estimated 3-year OS rates were 61.8% and 43.1% in AYA and young patients, respectively (P=0.005); the estimated 3-year CRFS rates were 35.8% and 22.6% in AYA and young patients, respectively (P=0.008); and the estimated 3-year GRFS rates were 26.7% and 15.1% in AYA and young patients, respectively (P=0.006). The estimated 3-year CIR were 36.3% and 39.3% in AYA and young patients, respectively (P=0.407); and the estimated 3-year NRM were 17.0% and 23.4% in AYA and young patients, respectively (P=0.113). In addition, the use of RIC regimen was associated with lower NRM than that of MAC regimen (P=0.015), but there was no significant difference of OS, CRFS, GRFS, and CIR between MAC and RIC regimens. The multivariate analyses revealed that young patients were significantly associated with worse OS (Hazard ratio (HR) [95% confidential interval], 1.62 [1.10-2.39]; P=0.015), CRFS (HR, 1.51 [1.10-2.06]; P=0.010), and GRFS (HR, 1.49 [1.11-1.99]; P=0.008) than AYA patients. The utilization of RIC regimen was significantly associated with lower NRM (HR, 0.46 [0.24-0.86]; P=0.015).

To find the optimal selection of conditioning intensity (MAC vs. RIC) by patient's age, we next evaluated the effect modification. In the subgroup analysis, there was significant interaction of conditioning intensity with patient's age (P interaction=0.002) in NRM but not in OS, CRFS, GRFS, and CIR. Among AYA patients, the estimated 1-year NRM were 12.5% and 18.8% in MAC and RIC regimens, respectively (P=0.085). Among young patients, the estimated 1-year NRM were 23.5% and 8.2% in MAC and RIC regimens, respectively (P&lt;0.001).

Conclusion

The present study clarified that AYA patients exhibited better post-transplant outcomes than young patients, indicating the prognostic value of patient's age in ATL patients aged &lt;50 years. Moreover, no significant differences were observed in OS, CRFS, GRFS, and CIR between RIC and MAC regimens, but the utilization of RIC regimen would reduce the risk of non-relapse death among young patients. These facts suggested that RIC regimen could be an alternative option for ATL patients aged 40-49 years.